DD255544A5 - Verfahren zur ortsselektiven Genommodifikation von Hefen der Gattung Pichia - Google Patents

Verfahren zur ortsselektiven Genommodifikation von Hefen der Gattung Pichia Download PDF

Info

Publication number: DD255544A5
Authority: DD; German Democratic Republic
Prior art keywords: gene; dna fragment; pichia; insertable dna; insertable
Prior art date: 1985-10-25

Application number

DD29558586A

Other languages

German (de)

English (en)

Original Assignee

Phillips Petroleum Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-10-25

Filing date

1986-10-24

Publication date

1988-04-06

1986-10-24 Application filed by Phillips Petroleum Co filed Critical Phillips Petroleum Co

1988-04-06 Publication of DD255544A5 publication Critical patent/DD255544A5/de

Links

241000235648 Pichia Species 0.000 title claims abstract description 66
238000000034 method Methods 0.000 title claims abstract description 37
240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 26
238000012239 gene modification Methods 0.000 title claims abstract description 8
108020004414 DNA Proteins 0.000 claims abstract description 121
239000012634 fragment Substances 0.000 claims abstract description 109
108090000623 proteins and genes Proteins 0.000 claims abstract description 88
108010025188 Alcohol oxidase Proteins 0.000 claims abstract description 40
239000003550 marker Substances 0.000 claims abstract description 33
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 17
239000013612 plasmid Substances 0.000 claims description 61
241000235058 Komagataella pastoris Species 0.000 claims description 32
101150006240 AOX2 gene Proteins 0.000 claims description 12
239000002773 nucleotide Substances 0.000 claims description 8
125000003729 nucleotide group Chemical group 0.000 claims description 8
230000001105 regulatory effect Effects 0.000 claims description 8
108010085336 phosphoribosyl-AMP cyclohydrolase Proteins 0.000 claims description 2
230000004308 accommodation Effects 0.000 claims 1
KDZOASGQNOPSCU-UHFFFAOYSA-N argininosuccinate Chemical compound OC(=O)C(N)CCCN=C(N)NC(C(O)=O)CC(O)=O KDZOASGQNOPSCU-UHFFFAOYSA-N 0.000 claims 1
230000014509 gene expression Effects 0.000 abstract description 23
238000004519 manufacturing process Methods 0.000 abstract description 10
150000003138 primary alcohols Chemical class 0.000 abstract description 8
230000001965 increasing effect Effects 0.000 abstract description 5
238000012986 modification Methods 0.000 abstract description 5
230000004048 modification Effects 0.000 abstract description 5
230000006798 recombination Effects 0.000 abstract description 2
238000005215 recombination Methods 0.000 abstract description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
210000004027 cell Anatomy 0.000 description 40
229920001817 Agar Polymers 0.000 description 36
239000008272 agar Substances 0.000 description 36
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 22
239000002609 medium Substances 0.000 description 22
239000013598 vector Substances 0.000 description 20
101150069554 HIS4 gene Proteins 0.000 description 19
238000003780 insertion Methods 0.000 description 19
230000037431 insertion Effects 0.000 description 19
230000012010 growth Effects 0.000 description 18
241000588724 Escherichia coli Species 0.000 description 17
230000008929 regeneration Effects 0.000 description 16
238000011069 regeneration method Methods 0.000 description 16
230000001131 transforming effect Effects 0.000 description 16
101150061183 AOX1 gene Proteins 0.000 description 15
239000000047 product Substances 0.000 description 15
230000009466 transformation Effects 0.000 description 15
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 13
229920001184 polypeptide Polymers 0.000 description 13
102000004196 processed proteins & peptides Human genes 0.000 description 13
108090000765 processed proteins & peptides Proteins 0.000 description 13
239000000600 sorbitol Substances 0.000 description 13
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 11
101710194180 Alcohol oxidase 1 Proteins 0.000 description 10
101150031623 aox gene Proteins 0.000 description 10
238000012217 deletion Methods 0.000 description 10
230000037430 deletion Effects 0.000 description 10
230000001580 bacterial effect Effects 0.000 description 9
238000010276 construction Methods 0.000 description 9
239000008103 glucose Substances 0.000 description 9
235000015097 nutrients Nutrition 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
102100036826 Aldehyde oxidase Human genes 0.000 description 8
230000000694 effects Effects 0.000 description 8
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 7
239000000872 buffer Substances 0.000 description 7
229910052799 carbon Inorganic materials 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
238000002105 Southern blotting Methods 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
239000007222 ypd medium Substances 0.000 description 6
108010067193 Formaldehyde transketolase Proteins 0.000 description 5
241000364057 Peoria Species 0.000 description 5
239000008121 dextrose Substances 0.000 description 5
239000000284 extract Substances 0.000 description 5
244000005700 microbiome Species 0.000 description 5
230000008569 process Effects 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
241000235070 Saccharomyces Species 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000000855 fermentation Methods 0.000 description 4
230000004151 fermentation Effects 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000000523 sample Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
101150033839 4 gene Proteins 0.000 description 3
101150005709 ARG4 gene Proteins 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
238000010804 cDNA synthesis Methods 0.000 description 3
229940041514 candida albicans extract Drugs 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000002950 deficient Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
208000002672 hepatitis B Diseases 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000035772 mutation Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000002689 soil Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
210000005253 yeast cell Anatomy 0.000 description 3
239000012138 yeast extract Substances 0.000 description 3
101710194173 Alcohol oxidase 2 Proteins 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
102100026189 Beta-galactosidase Human genes 0.000 description 2
BHKSYEZGBQDNRW-SCGRZTRASA-N C(CCC(=O)O)(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O Chemical compound C(CCC(=O)O)(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O BHKSYEZGBQDNRW-SCGRZTRASA-N 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
101000685990 Homo sapiens Specifically androgen-regulated gene protein Proteins 0.000 description 2
108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102100023355 Specifically androgen-regulated gene protein Human genes 0.000 description 2
239000007984 Tris EDTA buffer Substances 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
108010005774 beta-Galactosidase Proteins 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000010354 integration Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
101150066555 lacZ gene Proteins 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
108010082737 zymolyase Proteins 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
101150041132 AO gene Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010023063 Bacto-peptone Proteins 0.000 description 1
101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
AHQZRFBZJSCKAV-UHFFFAOYSA-N CC1=CCC=C1 Chemical compound CC1=CCC=C1 AHQZRFBZJSCKAV-UHFFFAOYSA-N 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
108020004638 Circular DNA Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
241001506991 Komagataella phaffii GS115 Species 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
108090000856 Lyases Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
108030001048 Secondary-alcohol oxidases Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
229940120503 dihydroxyacetone Drugs 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000012143 dye reagent concentrate Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
238000010362 genome editing Methods 0.000 description 1
231100000024 genotoxic Toxicity 0.000 description 1
230000001738 genotoxic effect Effects 0.000 description 1
230000001279 glycosylating effect Effects 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
230000010627 oxidative phosphorylation Effects 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
-1 polypropylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000011218 seed culture Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000011426 transformation method Methods 0.000 description 1
239000012137 tryptone Substances 0.000 description 1
101150043329 unpg gene Proteins 0.000 description 1
239000012808 vapor phase Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Investigating Or Analysing Materials By Optical Means (AREA)
Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Crystals, And After-Treatments Of Crystals (AREA)

DD29558586A 1985-10-25 1986-10-24 Verfahren zur ortsselektiven Genommodifikation von Hefen der Gattung Pichia DD255544A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/791,013 US4882279A (en)	1985-10-25	1985-10-25	Site selective genomic modification of yeast of the genus pichia

Publications (1)

Publication Number	Publication Date
DD255544A5 true DD255544A5 (de)	1988-04-06

Family

ID=25152397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD29558586A DD255544A5 (de)	1985-10-25	1986-10-24	Verfahren zur ortsselektiven Genommodifikation von Hefen der Gattung Pichia

Country Status (26)

Country	Link
US (1)	US4882279A (es)
EP (2)	EP0226752B1 (es)
JP (1)	JP2614215B2 (es)
KR (1)	KR930002738B1 (es)
CN (1)	CN86107108A (es)
AT (2)	ATE197962T1 (es)
AU (2)	AU581107B2 (es)
CA (1)	CA1339209C (es)
DD (1)	DD255544A5 (es)
DE (2)	DE3689411T2 (es)
DK (1)	DK510786A (es)
EG (1)	EG17985A (es)
ES (2)	ES2152233T3 (es)
FI (1)	FI98931C (es)
HU (1)	HU208552B (es)
IE (1)	IE68454B1 (es)
IL (1)	IL80286A (es)
IN (1)	IN166443B (es)
MX (1)	MX168390B (es)
NO (1)	NO176923C (es)
NZ (1)	NZ217809A (es)
PH (1)	PH25990A (es)
PL (1)	PL154843B1 (es)
PT (1)	PT83618B (es)
YU (1)	YU46758B (es)
ZA (1)	ZA867650B (es)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5032516A (en) *	1985-10-25	1991-07-16	Phillips Petroleum Company	Pichia pastoris alcohol oxidase II regulatory region
US4895800A (en) *	1985-11-26	1990-01-23	Phillips Petroleum Company	Yeast production of hepatitis B surface antigen
IL89989A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human interleukin-2 in methylotrophic yeasts
IL90021A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Process for the production of interferon
IL89993A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of the hiv 24kda gag protein in methylotrophic yeasts
IL89992A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human serum albumin in methylotrophic yeasts
IL89991A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of hepatitis b pres2 protein in methylotrophic yeasts
AT390267B (de) *	1988-06-08	1990-04-10	Vogelbusch Gmbh	Verfahren zum markieren und identifizieren von industriell eingesetzten mikroorganismen, vorzugsweise hefestaemmen
US5102789A (en) *	1989-03-15	1992-04-07	The Salk Institute Biotechnology/Industrial Associates, Inc.	Production of epideramal growth factor in pichia pastoris yeast cells
US5204252A (en) *	1989-02-08	1993-04-20	Henkel Research Corporation	Candida tropicalis transformation system
DD297841A5 (de) *	1989-02-13	1992-01-23	The Salk Institute Biotechnology/Industrial Associates,Us	Herstellung von superoxiddismutase in pichia pastoris hefezellen
JPH0669365B2 (ja) *	1989-05-22	1994-09-07	株式会社ミドリ十字	アルブミン遺伝子を含むプラスミド、形質転換体、形質転換体の製造方法、アルブミンの製造方法
CA2017176A1 (en) *	1989-05-22	1990-11-22	Yoshitomi Pharmaceutical Industries Ltd.	Albumin gene-containing plasmid, transformant carrying same, production of such transformant and production of albumin
US6440681B1 (en)	1990-04-03	2002-08-27	Merck & Co., Inc.	Methods for identifying agonists and antagonists for human neuronal nicotinic acetylcholine receptors
US5369028A (en) *	1990-04-03	1994-11-29	The Salk Institute Biotechnology/Industrial Associates, Inc.	DNA and mRNA encoding human neuronal nicotinic acetylcholine receptor compositions and cells transformed with same
US5258302A (en) *	1990-07-03	1993-11-02	The Salk Institute Biotechnology/Industrial Associates, Inc.	DNA for expression of aprotinin in methylotrophic yeast cells
EP0548267A4 (en) *	1990-09-04	1994-11-23	Salk Inst Biotech Ind	Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5612198A (en) *	1990-09-04	1997-03-18	The Salk Institute	Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5268273A (en) *	1990-12-14	1993-12-07	Phillips Petroleum Company	Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same
WO1992013951A1 (en) *	1991-02-04	1992-08-20	The Salk Institute Biotechnology/Industrial Associates, Inc.	Production of human serum albumin in methylotrophic yeast cells
CA2063890C (en) *	1991-03-27	2007-03-13	Masami Miura	Mutant aox2 promoter, microorganism carrying same, method of preparation thereof and production of heterologous protein using such microorganism
ATE220105T1 (de) *	1991-04-01	2002-07-15	Merck & Co Inc	Gene, die die proteolytische aktivitaet von pichia beeinflussen und deren verwendung
CA2058820C (en) *	1991-04-25	2003-07-15	Kotikanyad Sreekrishna	Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
US5330901A (en) *	1991-04-26	1994-07-19	Research Corporation Technologies, Inc.	Expression of human serum albumin in Pichia pastoris
US5665600A (en) *	1991-09-18	1997-09-09	Research Corporation Technologies, Inc.	Pichia pastoris linear plasmids and DNA fragments thereof
CZ225795A3 (en) *	1993-03-03	1996-02-14	Du Pont	Enzymatically active glycolate oxidase, process for preparing thereof, transformed methylotropic yeast, nucleic acid sequence and plasmid
CA2155330C (en)	1993-03-08	2002-01-29	Kathryn J. Elliott	Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
US5849895A (en)	1993-04-20	1998-12-15	Sibia Neurosciences, Inc.	Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor
HUT73395A (en) *	1993-05-28	1996-07-29	Du Pont	Process for preparing glyoxylic acid/dialkyl aminomethylphosphonate mixtures
US5521297A (en)	1993-06-04	1996-05-28	Salk Institute Biotechnology/Industrial Associates	Nucleic acids encoding human metabotropic glutamate receptors
US5912122A (en)	1993-06-04	1999-06-15	Sibia Neurosciences, Inc.	Nucleic acids encoding and method for detecting nucleic acid encoding human metabotropic glutamate receptor subtype mGluR6
US6001581A (en)	1993-06-04	1999-12-14	Sibia Neurosciences, Inc.	Cation-based bioassay using human metabotropic glutamate receptors
US6638905B2 (en) *	1993-06-18	2003-10-28	The Salk Institute For Biological Studies	Cloning and recombinant production of CFR receptor(s)
US6495343B1 (en)	1993-06-18	2002-12-17	The Salk Institute For Biological Studies	Cloning and recombinant production of CRF receptor(s)
WO1995013299A1 (en) *	1993-11-08	1995-05-18	The Salk Institute Biotechnology/Industrial Associates, Inc.	Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
EP0733059B1 (en) *	1993-12-09	2000-09-13	Thomas Jefferson University	Compounds and methods for site-directed mutations in eukaryotic cells
US5866543A (en) *	1995-06-05	1999-02-02	Corvas International, Inc.	Nematode-extracted anticoagulant protein
US5945275A (en) *	1994-10-18	1999-08-31	Corvas International, Inc.	Nematode-extracted anticoagulant protein
AU711405B2 (en) *	1994-10-18	1999-10-14	Dendreon Corporation	Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5863894A (en) *	1995-06-05	1999-01-26	Corvas International, Inc.	Nematode-extracted anticoagulant protein
US5866542A (en) *	1994-10-18	1999-02-02	Corvas International, Inc.	Nematode-extracted anticoagulant protein
US5872098A (en) *	1995-06-05	1999-02-16	Corvas International, Inc.	Nematode-extracted anticoagulant protein
CA2202351A1 (en) *	1994-10-18	1996-04-25	George Phillip Vlasuk	Nematode-extracted serine protease inhibitors and anticoagulant proteins
EP0815209B2 (en)	1995-03-17	2015-02-25	Novozymes A/S	Novel endoglucanases
US6485967B1 (en)	1995-06-07	2002-11-26	Merck & Co., Inc.	Human neuronal nicotinic acetylcholine receptor α6 and β3 nucleic acid
WO1997014786A1 (en) *	1995-10-18	1997-04-24	New York Blood Center, Inc.	RECOMBINANT α-N-ACETYLGALACTOSAMINIDASE ENZYME
US6001597A (en) *	1995-11-09	1999-12-14	Zymogenetics, Inc.	Compositions and methods for producing heterologous polypeptides in Pichia methanolica
JP2000500014A (ja) *	1995-11-09	2000-01-11	ザイモジェネティクス，インコーポレイティド	ピヒア・メタノリカ中で異種ポリペプチドを生産するための組成物と方法
DE69717092T2 (de)	1996-03-01	2003-07-24	Novo Nordisk A/S, Bagsvaerd	Gebrauch einer pharmazeutischen Zusammensetzung, enthaltend ein appetitzügelndes Peptid
US5731181A (en) *	1996-06-17	1998-03-24	Thomas Jefferson University	Chimeric mutational vectors having non-natural nucleotides
UA75316C2 (uk)	1996-10-16	2006-04-17	Займодженетікс, Інк.	Гомологи з фактором росту фібробласта
MX9605082A (es)	1996-10-24	1998-04-30	Univ Autonoma De Nuevo Leon	Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano.
IL142164A0 (en)	1998-09-23	2002-03-10	Zymogenetics Inc	Cytokine receptor zalpha11
AU764039B2 (en)	1998-12-07	2003-08-07	Zymogenetics Inc.	Growth factor homolog ZVEGF3
US6780615B1 (en)	1998-12-31	2004-08-24	Genway Biotech Inc.	Production of recombinant monellin using methylotrophic yeast expression system
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
DE60043626D1 (de)	1999-01-07	2010-02-11	Zymogenetics Inc	Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
EP1881070B1 (en)	1999-03-09	2012-10-03	Zymogenetics, Inc.	Human cytokine as ligand of the zalpha receptor and uses thereof
US7504253B2 (en) *	1999-06-11	2009-03-17	The Burnham Institute For Medical Research	Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
CA2378519C (en)	1999-07-07	2011-01-25	Zymogenetics, Inc.	Human cytokine receptor
DE60043944D1 (de)	1999-12-23	2010-04-15	Zymogenetics Inc	Zytokin zcyt018
ATE473280T1 (de)	2000-05-11	2010-07-15	Zymogenetics Inc	Zsig33-ähnliche peptide
CA2412239C (en)	2000-06-26	2013-05-28	Zymogenetics, Inc.	Cytokine receptor zcytor17
US7863020B2 (en)	2000-06-28	2011-01-04	Glycofi, Inc.	Production of sialylated N-glycans in lower eukaryotes
US7598055B2 (en) *	2000-06-28	2009-10-06	Glycofi, Inc.	N-acetylglucosaminyltransferase III expression in lower eukaryotes
US8697394B2 (en) *	2000-06-28	2014-04-15	Glycofi, Inc.	Production of modified glycoproteins having multiple antennary structures
EP2322644A1 (en)	2000-06-28	2011-05-18	GlycoFi, Inc.	Methods for producing modified glycoproteins
US7625756B2 (en)	2000-06-28	2009-12-01	GycoFi, Inc.	Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7449308B2 (en)	2000-06-28	2008-11-11	Glycofi, Inc.	Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US6927040B2 (en)	2000-06-30	2005-08-09	Zymogenetics, Inc.	Interferon-like protein Zcyto21
EP2267135A3 (en)	2000-06-30	2011-09-14	Vib Vzw	Protein glycosylation modification in pichia pastoris
US7009045B2 (en) *	2000-07-14	2006-03-07	Archer-Daniels-Midland Company	Transformation systems for flavinogenic yeast
EP1736545A3 (en)	2000-08-08	2007-03-28	ZymoGenetics, Inc.	Soluble zcytor 11 cytokine receptors
US20030012783A1 (en)	2001-02-20	2003-01-16	Wayne Kindsvogel	Antibodies that bind both BCMA and TACI
MXPA03008590A (es)	2001-03-22	2003-12-08	Novo Nordisk Healthcare Ag	Derivados del factor vii de coagulacion.
US6699691B2 (en)	2001-04-05	2004-03-02	The Board Of Regents Of The University Of Nebraska	Alcohol oxidase 1 regulatory nucleotide sequences for heterologous gene expression in yeast
BRPI0209933B8 (pt)	2001-05-24	2021-05-25	Zymogenetics Inc	proteína de fusão, e, molécula de ácido nucleico
DK1451322T3 (da)	2001-11-05	2010-02-01	Zymogenetics Inc	Il-21-antagonister
US7087418B2 (en) *	2001-12-19	2006-08-08	Bristol-Myers Squibb Company	Pichia pastoris formate dehydrogenase and uses therefor
ATE401390T1 (de)	2002-01-18	2008-08-15	Zymogenetics Inc	Zytokin (zcytor17-ligand)
AU2003280410B8 (en)	2002-01-18	2009-04-23	Zymogenetics, Inc.	Cytokine receptor zcytor17 multimers
US20060088834A1 (en) *	2002-04-15	2006-04-27	Gretchen Bain	Matrix analysis of gene expression in cells (magec)
EP2295455A1 (en)	2002-04-19	2011-03-16	ZymoGenetics, L.L.C.	Cytokine receptor
IL165717A0 (en)	2002-06-26	2006-01-15	Flanders Interuniversity Inst	A strain of methylotrophic yeast for producing proteins
ATE494367T1 (de) *	2002-12-18	2011-01-15	Hoffmann La Roche	Rekombinante desoxyribonuclease i aus rinder- pankreas mit hoher spezifischer aktivität
DE60319333D1 (de) *	2002-12-20	2008-04-10	Roche Diagnostics Gmbh	Hitzelabile Desoxyribonuklease I-Varianten
US7332299B2 (en) *	2003-02-20	2008-02-19	Glycofi, Inc.	Endomannosidases in the modification of glycoproteins in eukaryotes
EP1460425A1 (en) *	2003-03-17	2004-09-22	Boehringer Mannheim Gmbh	Deglycosylated enzymes for conjugates
EP1927600A1 (en)	2003-08-07	2008-06-04	Zymogenetics, Inc.	Homogeneous preparations of IL-28 and IL-29
ES2381110T3 (es)	2003-09-09	2012-05-23	Novo Nordisk Health Care Ag	Polipéptidos de factor VII de coagulación
ATE455849T1 (de) *	2003-12-05	2010-02-15	Hoffmann La Roche	Rekombinante carboxypeptidase b und ihre aufreinigung
US20070281332A1 (en)	2004-02-13	2007-12-06	Allan Svendsen	Protease Variants
ATE517914T1 (de)	2004-03-08	2011-08-15	Zymogenetics Inc	Dimere fusionsproteine und materialien und verfahren zu deren herstellung
CA2574564C (en)	2004-07-29	2013-04-16	Zymogenetics, Inc.	Use of il-28 and il-29 to treat cancer and autoimmune disorders
CN101001951B (zh)	2004-08-02	2011-06-15	巴斯福植物科学有限公司	分离转录终止序列的方法
EP2192132A3 (en)	2005-02-08	2010-08-18	ZymoGenetics, Inc.	Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
AU2006237329B2 (en)	2005-04-18	2012-04-12	Novo Nordisk A/S	IL-21 variants
EP3214095B1 (en)	2005-05-12	2019-12-11	ZymoGenetics, Inc.	Compositions and methods for modulating immune responses
US7393667B2 (en) *	2005-05-31	2008-07-01	Bristol-Myers Squibb Company	Stereoselective reduction process for the preparation of pyrrolotriazine compounds
AU2006278229B2 (en) *	2005-08-09	2011-10-27	Ares Trading S.A.	Methods for treating B-cell malignancies using TACI-Ig fusion molecule
EP1922079A2 (en)	2005-08-09	2008-05-21	ZymoGenetics, Inc.	Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
CN102660614A (zh)	2005-08-16	2012-09-12	诺沃-诺迪斯克有限公司	制备成熟胰岛素多肽的方法
JP5690047B2 (ja)	2005-09-14	2015-03-25	ノボノルディスクヘルスケアアーゲー	ヒト凝固第ｖｉｉ因子ポリペプチド
CA2621344C (en) *	2005-09-14	2014-12-16	Sanofi-Aventis Deutschland Gmbh	Cleavage of precursors of insulins by a variant of trypsin
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
EA015351B1 (ru)	2005-09-28	2011-06-30	Займодженетикс, Инк.	Антагонисты il-17a и il-17f и способы их применения
JP2009537563A (ja) *	2006-05-15	2009-10-29	アレストレーディングソシエテアノニム	Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
EP2069502B1 (en)	2006-09-27	2014-02-26	Novo Nordisk A/S	Method for making maturated insulin polypeptides
WO2008120107A2 (en)	2007-04-03	2008-10-09	Oxyrane (Uk) Limited	Glycosylation of molecules
US20100240597A1 (en)	2007-06-15	2010-09-23	Arkansas State University	Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
KR101700711B1 (ko)	2007-11-21	2017-01-31	로스킬드 유니베르시테트	얼음-결합 활성을 포함하는 폴리펩티드
CN101952309A (zh) *	2007-12-21	2011-01-19	Ifxa有限公司	蛋白酶抑制剂
AU2009207645B2 (en) *	2008-01-25	2014-11-13	Aarhus Universitet	Selective exosite inhibition of PAPP-A activity against IGFBP-4
JP5647009B2 (ja) *	2008-03-03	2014-12-24	アッヴィ・インコーポレイテッド	酵母を形質転換するための方法
WO2009120922A2 (en)	2008-03-27	2009-10-01	Zymogenetics, Inc.	Compositions and methods for inhibiting pdgfrbeta and vegf-a
WO2009139349A1 (ja) *	2008-05-14	2009-11-19	Ｂｉｏ－ｅｎｅｒｇｙ株式会社	酵母細胞に遺伝子を導入する方法およびそのためのベクター
JP2011526154A (ja)	2008-06-27	2011-10-06	ザイモジェネティクス，インコーポレイテッド	可溶性ハイブリッドＦｃγレセプターおよび関連する方法
US20110275535A1 (en)	2008-12-16	2011-11-10	Novartis Ag	Yeast Display Systems
CA2748314C (en)	2009-02-03	2018-10-02	Amunix Operating Inc.	Extended recombinant polypeptides and compositions comprising same
EP2406282A1 (en)	2009-03-11	2012-01-18	Novo Nordisk A/S	Interleukin-21 variants having antagonistic binding to the il-21 receptor
US20120282285A1 (en)	2009-07-17	2012-11-08	Rigshospitalet	Masp isoforms as inhibitors of complement activation
AU2010290131C1 (en)	2009-08-24	2015-12-03	Amunix Operating Inc.	Coagulation factor VII compositions and methods of making and using same
US9598682B2 (en)	2009-09-29	2017-03-21	Vib Vzw	Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
US20130053550A1 (en)	2009-11-19	2013-02-28	Oxyrane Uk Limited	Yeast strains producing mammalian-like complex n-glycans
US8815541B2 (en)	2009-11-25	2014-08-26	Novo Nordisk A/S	Method for making polypeptides
ES2583259T3 (es)	2009-12-01	2016-09-20	Novo Nordisk A/S	Nuevas liasas alfa-amidantes de peptidil alfa-hidroxiglicina
CA2791841C (en)	2010-03-05	2023-01-03	Rigshospitalet	Chimeric inhibitor molecules of complement activation
US8822642B2 (en)	2010-06-09	2014-09-02	Zymogenetics, Inc.	Dimeric fusion proteins and related compositions and methods
WO2012042387A2 (en)	2010-09-29	2012-04-05	Oxyrane Uk Limited	De-mannosylation of phosphorylated n-glycans
US9347050B2 (en)	2010-09-29	2016-05-24	Oxyrane Uk Limited	Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
BR112014015933A2 (pt)	2011-12-30	2019-09-24	Oxyrane Uk Ltd	métodos e materiais para reduzir a degradação das proteínas recombinantes
SG10201606285YA (en)	2012-02-01	2016-09-29	Synthetic Genomics Inc	Materials and methods for the synthesis of error-minimized nucleic acid molecules
AU2013217986B2 (en)	2012-02-09	2017-04-27	Var2 Pharmaceuticals Aps	Targeting of chondroitin sulfate glycans
BR112014020694A2 (pt)	2012-02-15	2018-05-08	Amunix Operating Inc.	proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (en)	2012-02-15	2013-08-22	Biogen Idec Ma Inc.	Recombinant factor viii proteins
EP3628326B1 (en)	2012-03-15	2024-02-28	Oxyrane UK Limited	Methods and materials for treatment of pompe's disease
KR101958234B1 (ko) *	2012-05-09	2019-03-14	엘지이노텍 주식회사	보이스 코일 모터
CN104704118A (zh)	2012-10-15	2015-06-10	诺和诺德保健Ag（股份有限公司）	凝血因子vii多肽
US20190040368A1 (en)	2013-03-05	2019-02-07	Oxyrane Uk Limited	Production of catalytically active type i sulfatase
EP2976352B1 (en)	2013-03-21	2021-08-18	Evonik Operations GmbH	Purification of triple helical proteins
JP2016521701A (ja)	2013-06-07	2016-07-25	ノヴォノルディスクアー／エス	成熟インスリンポリペプチドを作製するための方法
WO2014202089A2 (en)	2013-06-18	2014-12-24	Roskilde Universitet	Variants of anti-freeze polypeptides
US10548953B2 (en)	2013-08-14	2020-02-04	Bioverativ Therapeutics Inc.	Factor VIII-XTEN fusions and uses thereof
AU2014317807B2 (en)	2013-09-09	2019-02-21	Evonik Operations Gmbh	Modified bacterial collagen-like proteins
ES2897639T3 (es) *	2014-07-30	2022-03-02	Daiichi Sankyo Co Ltd	Método para la producción secretora de alto nivel mejorada de proteínas
BR112018002150A2 (pt)	2015-08-03	2018-09-18	Bioverativ Therapeutics Inc	proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
WO2017044424A1 (en)	2015-09-08	2017-03-16	Theripion, Inc.	Apoa-1 fusion polypeptides and related compositions and methods
EP3352760B1 (en)	2015-09-21	2026-03-11	Aptevo Research and Development LLC	Cd3 binding polypeptides
IL319473A (en)	2016-12-02	2025-05-01	Bioverativ Therapeutics Inc	Methods for treating hemophilic arthritis using chimeric blood clotting factors
WO2018136163A2 (en)	2016-12-09	2018-07-26	Theripion, Inc.	Tandem apoa-1 fusion polypeptides
EP3556856A4 (en) *	2016-12-15	2020-06-24	Kaneka Corporation	NOVEL HOST CELL AND TARGET PROTEIN PRODUCTION METHOD USING THE SAME
SG11202000503QA (en)	2017-07-20	2020-02-27	Aptevo Res & Development Llc	Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
BR112020012364A2 (pt)	2017-12-20	2020-11-24	Harbour Biomed (Shanghai) Co., Ltd	anticorpos de ligação a ctla-4 e usos dos mesmos
US10150801B1 (en)	2017-12-27	2018-12-11	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
EP3732190B1 (en)	2017-12-27	2025-08-06	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
DE202019005554U1 (de) *	2018-03-06	2021-01-18	Joywell Foods, Inc.	Rekombinant exprimierte geschmacksmodifizierende Polypeptide und Präparate und Formulierungen, die diese enthalten
BR112020022164A2 (pt)	2018-05-18	2021-02-02	Bioverativ Therapeutics Inc.	métodos de tratamento de hemofilia a
US20210278406A1 (en)	2018-07-13	2021-09-09	Varct Diagnostic Aps	Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa
CN111378585B (zh)	2018-12-28	2023-06-16	丰益(上海)生物技术研发中心有限公司	用于表达外源基因的毕赤酵母突变株
AU2020252241B2 (en) *	2019-04-01	2024-03-21	Universität Für Bodenkultur Wien	Mut- methylotrophic yeast
WO2021040610A1 (en)	2019-08-26	2021-03-04	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
US10675332B1 (en)	2019-08-26	2020-06-09	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
EP4168034B1 (en)	2020-06-22	2025-11-26	Imunami Laboratories Pte. Ltd.	Recombinant alpha-a-crystallin and combinations for use in the treatment of cancer
US12180521B2 (en)	2021-02-19	2024-12-31	Theripion, Inc.	Paraoxonase fusion polypeptides and related compositions and methods
CN120584137A (zh)	2023-01-06	2025-09-02	阿帕特夫研究和发展有限公司	双特异性pd-l1和cd40结合分子以及其用途
WO2024259220A1 (en)	2023-06-15	2024-12-19	Theripion, Inc.	Pon3 and evolved pon1 fusion polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4530901A (en) *	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4414329A (en) *	1980-01-15	1983-11-08	Phillips Petroleum Company	Biochemical conversions by yeast fermentation at high cell densities
JPS57206699A (en) *	1981-06-10	1982-12-18	Takeda Chem Ind Ltd	Plasmid patm 3 and its preparation
US4837148A (en) *	1984-10-30	1989-06-06	Phillips Petroleum Company	Autonomous replication sequences for yeast strains of the genus pichia
US4879231A (en) *	1984-10-30	1989-11-07	Phillips Petroleum Company	Transformation of yeasts of the genus pichia
US4855231A (en) *	1984-10-30	1989-08-08	Phillips Petroleum Company	Regulatory region for heterologous gene expression in yeast

1985
- 1985-10-25 US US06/791,013 patent/US4882279A/en not_active Expired - Lifetime
1986
- 1986-07-29 CA CA000514838A patent/CA1339209C/en not_active Expired - Lifetime
- 1986-10-06 NZ NZ217809A patent/NZ217809A/en unknown
- 1986-10-06 IE IE263786A patent/IE68454B1/en not_active IP Right Cessation
- 1986-10-07 ZA ZA867650A patent/ZA867650B/xx unknown
- 1986-10-08 IN IN731/CAL/86A patent/IN166443B/en unknown
- 1986-10-08 MX MX003971A patent/MX168390B/es unknown
- 1986-10-09 PH PH34343A patent/PH25990A/en unknown
- 1986-10-10 IL IL80286A patent/IL80286A/xx not_active IP Right Cessation
- 1986-10-14 AU AU63882/86A patent/AU581107B2/en not_active Expired
- 1986-10-20 JP JP61249403A patent/JP2614215B2/ja not_active Expired - Lifetime
- 1986-10-20 KR KR1019860008825A patent/KR930002738B1/ko not_active Expired - Fee Related
- 1986-10-22 EG EG659/86A patent/EG17985A/xx active
- 1986-10-23 YU YU180386A patent/YU46758B/sh unknown
- 1986-10-23 AT AT93105818T patent/ATE197962T1/de not_active IP Right Cessation
- 1986-10-23 ES ES93105818T patent/ES2152233T3/es not_active Expired - Lifetime
- 1986-10-23 AT AT86114700T patent/ATE98695T1/de not_active IP Right Cessation
- 1986-10-23 DE DE3689411T patent/DE3689411T2/de not_active Expired - Lifetime
- 1986-10-23 ES ES86114700T patent/ES2061433T3/es not_active Expired - Lifetime
- 1986-10-23 EP EP86114700A patent/EP0226752B1/en not_active Expired - Lifetime
- 1986-10-23 EP EP93105818A patent/EP0560401B1/en not_active Expired - Lifetime
- 1986-10-23 DE DE3650749T patent/DE3650749T2/de not_active Expired - Lifetime
- 1986-10-24 PT PT83618A patent/PT83618B/pt not_active IP Right Cessation
- 1986-10-24 CN CN198686107108A patent/CN86107108A/zh active Pending
- 1986-10-24 FI FI864319A patent/FI98931C/fi not_active IP Right Cessation
- 1986-10-24 HU HU864480A patent/HU208552B/hu not_active IP Right Cessation
- 1986-10-24 PL PL1986262030A patent/PL154843B1/pl unknown
- 1986-10-24 NO NO864275A patent/NO176923C/no unknown
- 1986-10-24 DK DK510786A patent/DK510786A/da not_active Application Discontinuation
- 1986-10-24 DD DD29558586A patent/DD255544A5/de unknown
1988
- 1988-04-15 AU AU14699/88A patent/AU593436B2/en not_active Expired

Also Published As

Publication number	Publication date
ATE98695T1 (de)	1994-01-15
DK510786A (da)	1987-04-26
NO864275D0 (no)	1986-10-24
IN166443B (es)	1990-05-12
DE3650749D1 (de)	2001-01-11
KR870004141A (ko)	1987-05-07
FI864319L (fi)	1987-04-26
IE68454B1 (en)	1996-06-26
HUT44612A (en)	1988-03-28
PT83618A (en)	1986-11-01
CN86107108A (zh)	1987-06-03
IE940325L (en)	1987-04-25
ATE197962T1 (de)	2000-12-15
FI98931B (fi)	1997-05-30
NZ217809A (en)	1991-07-26
NO176923C (no)	1995-06-21
IE862637L (en)	1987-04-25
YU46758B (sh)	1994-05-10
AU581107B2 (en)	1989-02-09
MX168390B (es)	1993-05-21
PH25990A (en)	1992-01-13
CA1339209C (en)	1997-08-05
DE3689411D1 (de)	1994-01-27
ZA867650B (en)	1987-05-27
DE3650749T2 (de)	2001-04-05
EP0560401B1 (en)	2000-12-06
DE3689411T2 (de)	1994-07-21
AU6388286A (en)	1987-04-30
JPS62104585A (ja)	1987-05-15
EP0560401A1 (en)	1993-09-15
PL154843B1 (en)	1991-09-30
FI98931C (fi)	1997-09-10
FI864319A0 (fi)	1986-10-24
IL80286A0 (en)	1987-01-30
KR930002738B1 (ko)	1993-04-09
NO864275L (no)	1987-04-27
EP0226752B1 (en)	1993-12-15
NO176923B (no)	1995-03-13
EG17985A (en)	1991-11-30
ES2061433T3 (es)	1994-12-16
IL80286A (en)	1991-12-12
AU1469988A (en)	1988-07-21
YU180386A (sh)	1992-12-21
US4882279A (en)	1989-11-21
PT83618B (pt)	1988-10-14
AU593436B2 (en)	1990-02-08
EP0226752A1 (en)	1987-07-01
DK510786D0 (da)	1986-10-24
HU208552B (en)	1993-11-29
PL262030A1 (en)	1987-09-07
JP2614215B2 (ja)	1997-05-28
ES2152233T3 (es)	2001-02-01

Legal Events

Date	Code	Title	Description
1994-07-21	RPI	Change in the person, name or address of the patentee (searches according to art. 11 and 12 extension act)
1994-07-21	RPV	Change in the person, the name or the address of the representative (searches according to art. 11 and 12 extension act)
2004-04-28	ASS	Change of applicant or owner	Owner name: RESEARCH CORPORATION TECHNOLOGIES, INC Effective date: 19940503
2004-04-28	IF04	In force in the year 2004	Expiry date: 20061025

Publication	Publication Date	Title
DD255544A5 (de)	1988-04-06	Verfahren zur ortsselektiven Genommodifikation von Hefen der Gattung Pichia
DE68929115T2 (de)	2000-06-15	Verfahren zur Herstellung von menschlichem Serumalbumin in Hefe
DE3688831T2 (de)	1993-11-25	Herstellung von Hepatitis-B-Oberflächen-Antigen-(HBsAg) mittels Hefe.
DE3888381T2 (de)	1994-07-28	Hefevektor.
DE3586858T2 (de)	1993-05-19	Transformation von aspergillus niger und dabei zu verwendende plasmide.
DE69232666T2 (de)	2003-03-20	Gene, die die proteolytische aktivitaet von pichia beeinflussen und deren verwendung
DD254211A5 (de)	1988-02-17	Verfahren zur herstellung von plypeptiden
DE3650664T2 (de)	1998-04-16	Verwendung von promotoren von filamentösen pilzen
DE3486206T2 (de)	1994-02-03	Expressionssysteme für Hefe mit PyK-Promotoren enthaltenden Vektoren und Synthese von Fremdproteinen.
DE69132812T2 (de)	2002-06-20	Pichia pastoris Säure-Phosphatase-Gen
DE69224768T2 (de)	1998-07-09	Expression von menschlichen Serum-Albuminen in Pichia pastoris
DE69805627T2 (de)	2002-11-28	Verbesserte stämme für die protein-expression
DE69735935T2 (de)	2007-05-10	Verfahren für die herstellung und aufreinigung von plasmid-dna
DE69506691T2 (de)	1999-06-10	Expressionskassette, die einen aus dem Schizosaccharomyces pombe-Pho4-Gene stammenden Promotor enthält
DE69027970T2 (de)	1997-01-16	Hefe-Promoter
DE3689918T2 (de)	1994-10-20	Verfahren zur Verwendung von BAR1 für die Fremdproteinsekretion.
DE69226028T2 (de)	1998-12-10	Mutanter AOX2 Promotor, Mikroorganismen es enthaltend, Verfahren zur Herstellung und Produktion von heterologem Protein, das solche Mikroorganismen benutz
DE69034051T2 (de)	2003-11-27	Stabil transformierte Hefezellen und ihre Verwendung zur Herstellung von Albumin
DE68907166T2 (de)	1993-10-21	Verfahren zur Herstellung von menschlichem Lysozym.
DE3782560T2 (de)	1993-06-03	Hefestaemme zur expression fremder gene.
DE60320573T2 (de)	2009-05-28	Verfahren zur expression und sekretion von proteinen mittels des nicht-konventionellen hefe zygosaccharomyces bailii
DE69325169T2 (de)	1999-12-30	Verfahren zur herstellung von häm-proteinen
DE3685985T2 (de)	1992-12-17	Mutanten von saccharomyces cerevisiae mit stark vermehrter sekretion.
DE69331434T2 (de)	2002-09-05	Mutanter AOX2 Promotor, diesen enthaltender Vektor, transformierte Zellen und Herstellung von heterologen Proteinen
EP0300425B1 (de)	1993-07-21	Verfahren zur Herstellung von Proteinen in löslicher Form